Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00406887
Status:
COMPLETED
Last Update Posted:
2006-12-04
First Post:
2006-11-29
Brief Title:
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
Sponsor:
Sirion Therapeutics Inc
Organization:
Sirion Therapeutics Inc
Study Overview
Official Title:
Phase 3 Confirmatory Study of 005 Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis Including Panuveitis
Status:
COMPLETED
Status Verified Date:
2006-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this phase 3 confirmatory study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of treatment of uveitis
Detailed Description:
The objective of this phase 3 study is to assess the efficacy and safety of 005 difluprednate ophthalmic emulsion DFBA in patients with endogenous anterior uveitis in comparison with 01 betamethasone sodium phosphate ophthalmic solution BP
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None